文献速递中医内科中药与中成药合理使用

莲子心主要生物碱甲基莲心碱通过靶向GSK3β与β-catenin信号减轻肾纤维化

Neferine, a major alkaloid from the traditional Chinese medicine Lian Zi Xin, alleviates renal fibrosis by targeting GSK3β and β-catenin signaling.
PubMed 文献 · J Ethnopharmacol · 2026-08-11

该研究探讨中药莲子心主要生物碱甲基莲心碱(Nef)对小鼠肾损伤的保护作用及机制。采用高糖刺激系膜细胞和TGF-β1诱导HK-2细胞的体外模型,以及高脂饮食联合链脲佐菌素诱导的糖尿病肾病(DN)模型和单侧输尿管梗阻(UUO)模型。结果显示Nef直接结合β-catenin和GSK3β,减少GSK3β Ser9磷酸化,抑制β-catenin蓄积和Wnt/β-catenin通路活性,从而改善肾纤维化。

要点

  • Nef直接结合β-catenin和GSK3β,抑制Wnt/β-catenin通路活性。
  • Nef减少FN、Col IV等细胞外基质成分并抑制上皮-间质转化。
  • Nef在DN和UUO模型中均减轻肾损伤,提示治疗纤维性肾病潜力。

核心结论

  • Nef通过靶向GSK3β和β-catenin抑制Wnt/β-catenin信号通路,改善DN和UUO诱导的肾损伤。

研究设计与样本

  • 体外建立高糖刺激系膜细胞和TGF-β1诱导HK-2细胞模型;体内建立高脂饮食联合链脲佐菌素诱导的DN模型和UUO模型,均给予Nef干预。

主要发现

  • Nef显著下调FN和Col IV等细胞外基质成分,并抑制细胞和动物模型中的上皮-间质转化。
  • Nef直接结合β-catenin和GSK3β,减少GSK3β Ser9磷酸化,阻止β-catenin蓄积并抑制Wnt/β-catenin通路活性。

关键数值与推荐

  • 通过生物信息学、pull-down实验和细胞热位移实验(CETSA)验证Nef与靶蛋白结合。
  • Western blot和免疫组化评估FN、Col IV及Wnt/β-catenin通路关键组分。

临床怎么用

  • 莲子心主要生物碱Nef可能作为靶向GSK3β/β-catenin通路的候选药物用于纤维性肾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Neferine (Nef) is the primary bioactive alkaloid of lotus seed germ (Lian Zi Xin), a traditional Chinese medicine long used for 'clearing heart fire' and ' eliminating internal heat, and regulating body fluid metabolism (e.g., promoting diuresis and reducing edema)'. From the perspective of modern medical concepts, 'internal heat' and 'fluid imbalance' often correspond to conditions such as impaired kidney function. AIM OF THE STUDY: To investigate the protective effects of Nef against renal injury in mice and identify the underlying mechanisms. MATERIALS AND METHODS: In vitro model of diabetic nephropathy (DN) and renal fibrosis were established using high glucose-stimulated mesangial cells and TGF-β1-induced HK-2 cells, respectively. In vivo model of DN and renal fibrosis were established by high-fat diet combined with streptozotocin, and unilateral ureteral obstruction (UUO), respectively. Nef intervention was applied in both models. Fibrotic markers such as fibronectin (FN), collagen IV (Col IV) and key components of the Wnt/β-catenin pathway were assessed by Western blot and immunohistochemistry. The binding between neferine and target proteins was validated through bioinformatics, pull-down assays, and cellular thermal shift assay (CETSA). The regulatory effects of Nef on GSK3β phosphorylation (Ser9) and β-catenin accumulation were further examined. RESULTS: Treatment with neferine results in significant downregulation of extracellular matrix components, such as FN and Col IV, along with inhibition of epithelial-mesenchymal transition in both cellular and animal models. At the molecular level, Nef exerts its effects by directly binding to β-catenin and GSK3β, reducing GSK3β phosphorylation at Ser9, which in turn prevents β-catenin accumulation and suppresses Wnt/β-catenin pathway activity. CONCLUSION: Nef ameliorates DN and UUO induced renal injury by targeting GSK3β and β-catenin, thereby inhibiting the Wnt/β-catenin signaling pathway. These findings highlight its therapeutic potential for fibrotic kidney diseases.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Li J, Qin Y, Yu Z, et al. Neferine, a major alkaloid from the traditional Chinese medicine Lian Zi Xin, alleviates renal fibrosis by targeting GSK3β and β-catenin signaling. J Ethnopharmacol. 2026. PMID: 42580543. doi:10.1016/j.jep.2026.122288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。